Abstract 107P
Background
Tumor stroma consists of a complex network of safeguards for tumor proliferation. Tumour stromal imaging using fibroblast-activated protein-tagged radionuclide provides a metabolic-radiological quantum of tumor stromal content. Tumors rich in stroma have been traditionally associated with poorer disease-free outcomes. Our study correlates between standard uptake values (SUV) in fibroblast imaging to tumor stromal ratio evaluated pathologically and the response to radiation therapy in locally advanced carcinoma rectum.
Methods
50 patients of carcinoma Rectum with all patients having undergone cancer associated Fibroblast PET CT scan prior to starting neoadjuvant chemoradiation. Tumors having SUV max > 10 were considered as High. Metabolic activity in tumor site was compared to Tumor stromal ratio and response to radiation was evaluated in histopathological report. Patients were classified into High TSR (<50% Stromal content) and Low Tumor Stroma Ratio (>50% Stromal content).
Results
7 patients who had complete pathological response all had high TSR and SUV mean 20.4. 34 patients had <50% residual disease 67% had high TSR and SUV mean 17.6 and 34% had low TSR and SUV mean of 21.44. 9 patients had >50% residual disease had 77% low TSR and high SUV mean 25.11(Range- 9.51-92.33). Patients with both Low TSR [ >50% stromal content] and SUV Max > 10 have poor pathological response compared to patients with low TSR. In the low stromal content irrespective of SUV the local control was good. Table: 107P
| High TSR | Low TSR | High SUV | Low SUV | |
| Complete response | 7(32%) | 0 | 4(15.4%) | 3(12.5%) |
| <50% Residual disease | 23(71.8%) | 11(61%) | 14(53.8%) | 20(83.3%) |
| >50% Residual disease | 2(6.2%) | 7(39%) | 8(30.8%) | 1(4.2%) |
Conclusions
High Tumor Stromal Ratio showed better complete and partial response to neoadjuvant chemoradiation in locally advanced carcinoma rectum. Tumors with high stromal content were observed to have higher SUV values in fibroblast stromal imaging and the same were also more commonly associated with suboptimal response. The need for dose escalation for the same has to be explored for better tumor control.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract